BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease.

华盛顿州博瑟尔，2024年4月11日（环球通讯社）--Athira Pharma，Inc.（纳斯达克：ATHA），一家临床晚期生物制药公司，专注于开发小分子以恢复神经元健康和减缓神经退行性疾病，今天宣布发表临床前数据，支持fosgonimeton在阿尔茨海默氏病中的治疗潜力。

The original research article, “Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics. Fosgonimeton is a potentially first-in-class, once daily, subcutaneously administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system, and is in development for neurodegenerative disorders, including Alzheimer’s disease..

Reda，s。等人撰写的原始研究文章“Fosgonimeton减弱阿尔茨海默病临床前模型中的β淀粉样蛋白毒性”发表在同行评审的期刊Neurotherapeutics上。Fosgonimeton是一种潜在的一流，每天一次，皮下给药的小分子候选药物，旨在增强神经营养性肝细胞生长因子（HGF）系统，正在开发用于神经退行性疾病，包括阿尔茨海默氏病。。

“These data continue to highlight the potential of fosgonimeton as a novel therapeutic approach for Alzheimer's disease targeting multiple facets of its complex pathophysiology,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira. “By positively modulating the HGF signaling system, fosgonimeton demonstrated neuroprotective and neurotrophic effects, countering mechanisms of amyloid-beta (Aβ)-induced toxicity both in vitro and in vivo.

Athira首席科学官Kevin Church博士说：“这些数据继续突显了fosgonimeton作为针对阿尔茨海默病复杂病理生理学多个方面的新型治疗方法的潜力。”。“通过积极调节HGF信号系统，fosgonimeton在体外和体内均表现出神经保护和神经营养作用，对抗淀粉样蛋白β（Aβ）诱导的毒性机制。

Our preclinical findings describe several mechanisms by which fosgonimeton may disrupt the neurodegenerative cascade of Alzheimer’s disease downstream of Aβ toxicity, including reduction of mitochondrial oxidative stress and excitotoxicity, improvement of autophagic pathway function, and attenuation of tau hyperphosphorylation.”.

我们的临床前研究结果描述了fosgonimeton可能破坏Aβ毒性下游阿尔茨海默病神经退行性级联反应的几种机制，包括减少线粒体氧化应激和兴奋毒性，改善自噬途径功能以及减弱tau蛋白过度磷酸化。”。

Key findings reported in the study publication regarding fosgonimeton in preclinical models of Alzheimer’s disease include:

研究出版物中关于fosgonimeton在阿尔茨海默病临床前模型中的主要发现包括：

In primary rat cortical neurons challenged with Aβ, fosgonimeton treatment improved neuronal survival, protected neurite networks, and reduced tau hyperphosphorylation following Aβ injury.

在用Aβ攻击的原代大鼠皮质神经元中，fosgonimeton治疗改善了神经元存活，保护了神经突网络，并减少了Aβ损伤后的tau过度磷酸化。

Fosgonimeton attenuated Aβ-induced mitochondrial stress and apoptotic signaling.

Fosgonimeton减弱了Aβ诱导的线粒体应激和凋亡信号传导。

Fosgonimeton enhanced activation of pro-survival effectors extracellular signal-regulated kinase (ERK) and protein kinase B (AKT). It also reduced activity of glycogen synthase kinase 3 beta (GSK3β), one of the main kinases involved in tau hyperphosphorylation.

Fosgonimeton增强促存活效应物细胞外信号调节激酶（ERK）和蛋白激酶B（AKT）的激活。它还降低了糖原合酶激酶3β（GSK3β）的活性，GSK3β是参与tau过度磷酸化的主要激酶之一。

Fosgonimeton mitigated Aβ-induced deficits in Unc-like kinase 1 (ULK1) and Beclin-1 expression, suggesting a potential effect on autophagy.

Fosgonimeton减轻了Aβ诱导的Unc样激酶1（ULK1）和Beclin-1表达缺陷，表明对自噬有潜在影响。

Fosgonimeton improved cognitive performance in an Aβ rat model of Alzheimer’s disease.

Fosgonimeton改善了阿尔茨海默病Aβ大鼠模型的认知能力。

“There is an urgent need for new treatments that tackle the multifactorial pathologies of Alzheimer’s disease (AD), especially for people with mild-to-moderate AD, an advanced stage of the disease,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “These preclinical data published in a peer-reviewed journal suggest that fosgonimeton counteracts aspects of AD pathology that lead to neurodegeneration.

Athira总裁兼首席执行官马克·利顿（Mark Litton）博士说：“迫切需要新的治疗方法来解决阿尔茨海默病（AD）的多因素病理，特别是对于患有轻度至中度AD的晚期患者。”。“这些发表在同行评审期刊上的临床前数据表明，fosgonimeton抵消了导致神经退行性疾病的AD病理学方面。

These findings bolster our confidence in the Phase 2/3 LIFT-AD trial evaluating fosgonimeton in mild-to-moderate AD, with data anticipated in the second half of 2024.”.

这些发现增强了我们对评估轻度至中度AD中fosgonimeton的2/3期LIFT-AD试验的信心，预计数据将在2024年下半年公布。”。

The article is available on the Neurotherapeutics website and from the Scientific Publications & Presentations page of the company’s website at www.athira.com.

这篇文章可以在Neurotherapeutics网站和该公司网站的科学出版物和演示页面上找到，网址为www.athira.com。

About Fosgonimeton

关于Phosgonimetone

Fosgonimeton is a potentially first-in-class, once daily, subcutaneously administered small molecule drug candidate. Targeting the protection and repair of neuronal networks, fosgonimeton has disease-modifying potential to address a broad range of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and dementia with Lewy bodies..

Fosgonimeton是一种潜在的一流，每天一次，皮下给药的小分子候选药物。针对神经元网络的保护和修复，fosgonimeton具有改善疾病的潜力，可以解决广泛的神经退行性疾病，包括阿尔茨海默氏病，帕金森氏病和路易体痴呆症。。

About Athira Pharma, Inc.

关于Athira Pharma，Inc。

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024.

Athira Pharma，Inc.，总部位于华盛顿州西雅图市，是一家临床晚期生物制药公司，专注于开发小分子以恢复神经元健康和减缓神经变性。Athira旨在通过推进其调节神经营养性HGF系统的候选治疗药物管道来改变神经系统疾病的进程，包括fosgonimeton，该药物正在2/3期LIFT-AD试验中评估轻度至中度阿尔茨海默氏病的潜在治疗方法，预计将在2024年下半年报告topline数据。